Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $3.7 million.

  • Fennec Pharmaceuticals' Accumulated Expenses rose 11.71% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 11.71%. This contributed to the annual value of $3.4 million for FY2024, which is 8.68% down from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Accumulated Expenses stood at $3.7 million for Q3 2025, which was up 66.34% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Accumulated Expenses ranged from a high of $4.4 million in Q1 2024 and a low of $171,000 during Q2 2021.
  • In the last 3 years, Fennec Pharmaceuticals' Accumulated Expenses had a median value of $3.0 million in 2024 and averaged $2.7 million.
  • Over the last 5 years, Fennec Pharmaceuticals' Accumulated Expenses had its largest YoY gain of 327.86% in 2021, and its largest YoY loss of 60.69% in 2021.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Accumulated Expenses stood at $860,000 in 2021, then tumbled by 54.19% to $2.2 million in 2022, then skyrocketed by 69.18% to $3.8 million in 2023, then dropped by 8.68% to $3.4 million in 2024, then grew by 11.71% to $3.7 million in 2025.
  • Its Accumulated Expenses stands at $3.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.8 million for Q1 2025.